Crossject SA

Paris Stock Exchange ALCJ.PA

Crossject SA Total Non-Current Liabilities for the year ending December 31, 2023: USD 26.31 M

Crossject SA Total Non-Current Liabilities is USD 26.31 M for the year ending December 31, 2023, a 20.67% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Crossject SA Total Non-Current Liabilities for the year ending December 31, 2022 was USD 21.80 M, a -37.39% change year over year.
  • Crossject SA Total Non-Current Liabilities for the year ending December 31, 2021 was USD 34.83 M, a 11.27% change year over year.
  • Crossject SA Total Non-Current Liabilities for the year ending December 31, 2020 was USD 31.30 M, a 71.37% change year over year.
  • Crossject SA Total Non-Current Liabilities for the year ending December 31, 2019 was USD 18.26 M, a 146.44% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
SV Wall Street
Paris Stock Exchange: ALCJ.PA

Crossject SA

CEO Mr. Patrick Alexandre
IPO Date Feb. 20, 2014
Location France
Headquarters 6 Rue Pauline Kergomard
Employees 105
Sector Healthcare
Industries
Description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Similar companies

NANO.PA

Nanobiotix S.A.

USD 3.47

-1.52%

ALBIO.PA

Biosynex SA

USD 1.18

2.98%

StockViz Staff

February 7, 2025

Any question? Send us an email